| Myasthenia Gravis, Generalized
Rystiggo vs Vyvgart Hytrulo
Side-by-side clinical, coverage, and cost comparison for myasthenia gravis, generalized.Deep comparison between: Rystiggo vs Vyvgart Hytrulo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVyvgart Hytrulo has a higher rate of injection site reactions vs Rystiggo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vyvgart Hytrulo but not Rystiggo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rystiggo
Vyvgart Hytrulo
At A Glance
SC injection
Once weekly (6-week cycles)
FcRn blocker
SC injection
Once weekly
FcRn blocker
Indications
- Myasthenia Gravis, Generalized
- Myasthenia Gravis, Generalized
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Dosing
Myasthenia Gravis, Generalized Weight-based SC infusion once weekly for 6 weeks: less than 50 kg: 420 mg (3 mL); 50 to less than 100 kg: 560 mg (4 mL); 100 kg and above: 840 mg (6 mL); administer at up to 20 mL/hour; subsequent cycles based on clinical evaluation, no sooner than 63 days from start of previous cycle.
Myasthenia Gravis, Generalized 1,000 mg efgartigimod alfa/10,000 units hyaluronidase SC once weekly for 4-week cycles (prefilled syringe over 20-30 seconds) or 1,008 mg/11,200 units (vial over 30-90 seconds); subsequent cycles based on clinical evaluation.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1,000 mg efgartigimod alfa/10,000 units hyaluronidase SC once weekly (prefilled syringe over 20-30 seconds) or 1,008 mg/11,200 units (vial over 30-90 seconds); continue based on clinical response.
Contraindications
—
- Serious hypersensitivity to efgartigimod alfa products, hyaluronidase, or any excipient of VYVGART HYTRULO (including anaphylaxis and hypotension leading to syncope)
Adverse Reactions
Most common (>=10%) headache, infections, diarrhea, pyrexia, hypersensitivity reactions, nausea
Serious infections (including fatal pneumonia), aseptic meningitis
Postmarketing herpes zoster
Most common (>=10%) Injection site reactions (rash, erythema, pruritus, bruising, pain, urticaria), headache
Serious Infections, hypersensitivity reactions (including anaphylaxis and hypotension), infusion/injection-related reactions
Postmarketing Hypersensitivity reactions including anaphylaxis and hypotension, infusion/injection-related reactions, worsening of CIDP symptoms when transitioning from intravenous immunoglobulin treatment
Pharmacology
FcRn antagonist; rozanolixizumab-noli is a humanized IgG4 monoclonal antibody that binds to the neonatal Fc receptor (FcRn), reducing circulating IgG levels and pathogenic AChR and MuSK autoantibody concentrations in patients with generalized myasthenia gravis.
Efgartigimod alfa, a human IgG1 Fc fragment, binds to the neonatal Fc receptor (FcRn) and reduces circulating IgG; co-formulated hyaluronidase transiently depolymerizes hyaluronan to increase subcutaneous tissue permeability for 24 to 48 hours.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rystiggo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Vyvgart Hytrulo
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Rystiggo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Vyvgart Hytrulo
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (0/8)
Humana
Rystiggo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Vyvgart Hytrulo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Myasthenia Gravis - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Vyvgart Hytrulo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RystiggoView full Rystiggo profile
Vyvgart HytruloView full Vyvgart Hytrulo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.